Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
Bausch Health Companies Inc. (BHC) and its subsidiary, Salix Pharmaceuticals, have filed a patent lawsuit against Amneal Pharmaceuticals in New Jersey, concerning Amneal's attempt to market a generic version of XIFAXAN®. Amneal's ANDA claims that the patents for XIFAXAN® are unenforceable, invalid, or not infringed. This lawsuit triggers a 30-month stay on FDA approval for Amneal's product. Bausch Health has defended its XIFAXAN® intellectual property against other companies in the past, with some cases settled and one ongoing.
April 05, 2024 | 10:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amneal Pharmaceuticals faces a lawsuit from Bausch Health over its ANDA for a generic version of XIFAXAN®, potentially delaying its market entry and impacting its growth prospects in the short term.
Amneal Pharmaceuticals' attempt to enter the market with a generic version of XIFAXAN® has been challenged by Bausch Health, triggering a 30-month stay on FDA approval. This legal action could significantly delay Amneal's product launch and impact its growth prospects in the short term, as it prevents the company from capitalizing on the market for generic gastrointestinal treatments.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90
POSITIVE IMPACT
Bausch Health's lawsuit against Amneal Pharmaceuticals over XIFAXAN® patents could protect its revenue from generic competition, maintaining its market share in the gastrointestinal health sector.
The lawsuit against Amneal Pharmaceuticals is a strategic move by Bausch Health to protect its XIFAXAN® franchise from generic competition. Given the company's history of defending its intellectual property and the potential 30-month stay on FDA approval for Amneal's ANDA, this action is likely to have a positive short-term impact on BHC's stock by maintaining its revenue stream from XIFAXAN®.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90